Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Inventory (2022 - 2026)

bioAffinity Technologies has reported Inventory over the past 5 years, most recently at $77887.0 for Q1 2026.

  • Quarterly Inventory rose 100.83% to $77887.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $77887.0 through Mar 2026, up 100.83% year-over-year, with the annual reading at $53548.0 for FY2025, 93.96% up from the prior year.
  • Inventory was $77887.0 for Q1 2026 at bioAffinity Technologies, up from $53548.0 in the prior quarter.
  • Over five years, Inventory peaked at $77887.0 in Q1 2026 and troughed at $5540.0 in Q4 2022.
  • The 5-year median for Inventory is $25363.0 (2024), against an average of $26848.7.
  • Year-over-year, Inventory decreased 16.3% in 2024 and then soared 308.79% in 2025.
  • A 5-year view of Inventory shows it stood at $5540.0 in 2022, then surged by 233.65% to $18484.0 in 2023, then soared by 49.36% to $27608.0 in 2024, then soared by 93.96% to $53548.0 in 2025, then soared by 45.45% to $77887.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Inventory are $77887.0 (Q1 2026), $53548.0 (Q4 2025), and $35234.0 (Q3 2025).